Cilomilast (Ariflo, SB-207,499) is a drug which was developed for the treatment of respiratory disorders such as asthma and Chronic Obstructive Pulmonary Disease (COPD). It is orally active and acts as a selective Phosphodiesterase-4 inhibitor. Clinical trial results showed reasonable efficacy for treating COPD, but side effects were problematic and it is unclear whether cilomalast will be marketed, or merely used in the development of newer drugs. Cilomilast is a second-generation PDE4 inhibitor with antiinflammatory effects that target bronchoconstriction, mucus hypersecretion, and airway remodeling associated with COPD.
PDE Inhibitors Related Products:
Roflumilast; Sildenafil citrate; Tadalafil; Pimobendan; GSK256066; Mardepodect; Rolipram; Apremilast; Milrinone; Avanafil; Ziritaxestat; Ibudilast; Balipodect; PF8380; Deltarasin; Anagrelide hydrochloride; Enpp-1-IN-1; Crisaborole; CP671305